Career history of Matthew D. Dallas
Former positions of Matthew D. Dallas
| Companies | Position | Start | End |
|---|---|---|---|
| ZEALAND PHARMA A/S | Director of Finance/CFO | 2019-10-06 | 2022-08-30 |
| Investor Relations Contact | 2019-10-06 | 2022-08-30 | |
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Director/Board Member | 2018-11-05 | 2020-02-02 |
| Independent Dir/Board Member | 2018-11-05 | 2020-02-02 | |
| AVEO PHARMACEUTICALS, INC. | Director of Finance/CFO | 2017-05-31 | 2019-09-25 |
| COLUCID PHARMACEUTICALS INC | Director of Finance/CFO | 2015-02-08 | 2017-02-28 |
| Treasurer | 2015-02-08 | 2017-02-28 | |
| AVEO PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 2014-06-30 | 2015-02-05 |
| Treasurer | 2014-06-30 | 2015-02-05 |
Training of Matthew D. Dallas
| University of Tennessee | Undergraduate Degree |
Statistics
International
| United States | 5 |
| Denmark | 2 |
Operational
| Director of Finance/CFO | 3 |
| Treasurer | 2 |
| Comptroller/Controller/Auditor | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| Private companies | 2 |
|---|---|
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Matthew D. Dallas
- Experience